Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 6

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 flows from financing activity        (Repayments)/Advances from Directors  (860)  26,930 Net cash (used in)/generated from financing activity  (860)  26,930          Foreign currency translation adjustment  43,050   (72,443)NET CHANGE IN CASH AND CASH EQUIVALENTS  (797,528)  (79,016)CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL PERIOD  2,886,966   4,517,710          CASH AND CASH EQUIVALENTS, END OF FINANCIAL PERIOD $2,089,438  $4,438,694          CASH AND CASH EQUIVALENTS INFORMATION:        Fixed deposits placed with financial institutions with original maturities of three months or less $998,237  $1,949,479 Cash at bank  1,091,201   2,489,215 Cash and cash equivalents, end of financial period  2,089,438   4,438,694          Supplementary cash flow information:        Interest paid $(1,545) $(2,711)Income tax paid  (4,924)  (14,517)

See accompanying notes to the condensed consolidated financial statements.

 8Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“BioNexus Malaysia”). BioNexus Malaysia was incorporated in Malaysia on April 7, 2015 and subsequently changed its name to MRNA Scientific Sdn. Bhd. (“MRNA Scientific”) on September 19, 2023. The principal office address is Unit A-28-7, Level 28